Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme A reductase inhibitor treatment of combined dyslipidemia

Metabolism: Clinical and Experimental

Volumn 51, Issue 10, 2002, Pages 1355-1359

  McLaughlin, Tracey ^a,b   Abbasi, Fahim ^a,b   Lamendola, Cindy ^a,b   Leary, Elizabeth ^a,b   Reaven, Gerald M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pacific Biometrics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036798102     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.34713     Document Type: Article

References (23)

1. Hayden JM, Reaven PD: Cardiovascular disease in diabetes mellitus type 2: A potential role for novel cardiovascular risk factors. Curr Opin Lipidol 11:519-528, 2000
2. Albrink JM: Dietary and drug treatment of hyperlipidemia in diabetes. Diabetes 423:913-918, 1974
3. Reaven GM, Chen Y-DI: Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 4:639-652, 1988
4. Fontbonne A, Eschwege E, Cambien RJL, et al: Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance of diabetes. Diabetologia 32:300-304, 1989
5. Pyorala K, Pedersen TR, Kjekshus J, et al: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20:614-620, 1997
6. Sacks FM, Pfeffer MA, Moye LA, et al: The cholesterol and recurrent events trial investigators: The effect of pravastatin of coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
7. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264:71-75, 1990
8. Shepherd J: Fibrates and statins in the treatment of hyperlipidemia: An appraisal of their efficacy and safety. Eur Heart J 16:5-15, 1995
9. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 341:498-511, 1997
10. Simons LA, Dwyer T, Simons J, et al: Chylomicrons and chylomicron remnants in coronary artery disease: A case-control study. Atherosclerosis 65:181-189, 1987
11. Simpson HS, Williamson CM, Olivecrona T, et al: Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 85: 193-202, 1990
12. Groot PH, Van Stiphout WA, Krauss XH, et al: Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb Vasc Biol 11:652-662, 1991
13. Patsch JR, Miesenbock G, Hopferwieser T, et al: Relation of triglyceride metabolism and coronary artery disease: Studies in the postprandial state. Arterioscler Thromb Vasc Biol 12:1336-1345, 1992
14. Karpe F, Bard JM, Steiner G, et al: HDLs and alimentary lipemia: Studies in men with previous myocardial infarction at young age. Arterioscler Thromb Vasc Biol 13:11-22, 1993
15. Zilversmit DB: Atherogenesis: A postprandial phenomenon. Circulation 60:473-485, 1979
16. Nestel PJ: Relationship between plasma triglycerides and removal of chylomicrons. J Clin Invest 43:943-949, 1964
17. Wilson DE, Chan I-F, Buchi KN, et al: Postchallenge plasma lipoprotein retinoids: Chylomicron remnants in endogenous hypertriglyceridemia. Metabolism 34:551-558, 1985
18. Bilheimer DW, Grundy SM, Brown MS, et al: Mevinolin and colestipol stimulate receptor-mediated clearance of low-density lipoprotein from plasma in familial hypercholesterolemic and combined hyperinsulinemic men: The Dietary Alternatives Study. JAMA 278:1509-1515, 1983
19. Vega G-L, Grundy SM: Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 81:36B-42B, 1998
20. Chen Y-DI, Swami S, Skowronski R, et al: Differences in postprandial lipemia between patients with normal glucose tolerance and non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 76:347-351, 1993
21. Jeppesen J, Schaaf P, Jones C, et al: Effects of low-fat, high carbohydrate diets on risk factors for ischemic heart disease in post-menopausal women. Am J Clin Nutr 65:1027-1033, 1997
22. Campos E, Nakajima K, Tanaka A, et al: Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 33:369-380, 1992
23. Leary ET, Wang T, Baker DJ, et al: Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 44:2490-2498, 1998